UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition

Abbott Laboratories (NYSE:ABT) ranks among the best slow growth stocks to invest in. UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (NYSE:ABT) on November 21 in response to the company’s agreed acquisition of Exact Sciences.

In the largest acquisition in the medtech sector thus far this year, Abbott Laboratories (NYSE:ABT) signed a formal agreement to buy Exact Sciences at $105 per share. The deal is scheduled for completion in the second quarter of 2026. Abbott’s Diagnostics division is expected to rise by about 300 basis points as a result of the transaction.

Abbott’s medical device businesses, which are primarily focused on diabetes and cardiovascular disease, will now venture into cancer care with this acquisition. Abbott Laboratories (NYSE:ABT) will also add Exact Sciences’ flagship test, Cologuard, which screens for colorectal cancer, to its portfolio.

Beyond Diagnostics, UBS is adamant that Abbott Laboratories (NYSE:ABT) will consistently outperform its competitors in sales and earnings per share starting in 2026, given its medical technology profile and persistent double-digit growth.

Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.